NuCana plc Stock News

EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will partici

Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022

Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.

Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.

Analysts expect that NuCana plc (NASDAQ:NCNA) will post ($0.25) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for NuCanas earnings, with estimates ranging from ($0.29) to ($0.17). NuCana reported earnings per share of ($0.32) during the same quarter last year, which suggests a positive year over []

Goldman Sachs Group Inc. bought a new position in shares of NuCana plc (NASDAQ:NCNA) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 39,332 shares of the companys stock, valued at approximately $109,000. Goldman Sachs Group Inc. owned 0.08% of NuCana at the end [] The post 39,332 Shares in NuCana plc (NASDAQ:NCNA) Acquired by Goldman Sachs Group Inc. appeared first on ETF Daily News .

NuCana: Preparing For A Critical 2022

NuCana plc (NASDAQ:NCNA) has a beta value of 0.73 and has seen 0.73 million shares traded in the recent trading session. The company, currently valued at $140.64M, closed the recent trade at $2.75 per share which meant it lost -$0.04 on the day or -1.56% during that session. The NCNA stock price is -184.73% off Here Is A Bargain Stock You Should Look At : NuCana plc (NCNA) Read More »

Brokerages predict that NuCana plc (NASDAQ:NCNA) will announce ($0.25) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for NuCanas earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.29). NuCana reported earnings of ($0.32) per share in the same quarter last year, which indicates a []

During the last session, NuCana plc (NASDAQ:NCNA)s traded shares were 0.36 million, with the beta value of the company hitting 0.73. At the end of the trading day, the stocks price was $2.84, reflecting an intraday gain of 7.98% or $0.21. The 52-week high for the NCNA share is $7.83, that puts it down -175.7 Does NuCana plc (NASDAQ: NCNA) Still Look Attractive After A 5.58% Selloff Last Week? Read More »

NuCana plc (NASDAQ:NCNA) Investment analysts at Oppenheimer upped their FY2024 earnings per share (EPS) estimates for shares of NuCana in a report issued on Tuesday, November 23rd. Oppenheimer analyst L. Gershell now expects that the company will post earnings of $0.08 per share for the year, up from their prior estimate of $0.04. Several []

NuCana plc (NASDAQ:NCNA) Equities research analysts at Truist Securiti upped their FY2021 earnings per share (EPS) estimates for NuCana in a research report issued to clients and investors on Monday, November 22nd. Truist Securiti analyst R. Karnauskas now forecasts that the company will post earnings per share of ($1.11) for the year, up from []

Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022

The stock price of NuCana PLC (NASDAQ: NCNA) increased by over 20% during intraday trading today. This is why it happened.

The FDA has granted Fast Track designation to NuCana plc's (NASDAQ: NCNA) Acelarin (NUC-1031) for the first-line treatment of patients with advanced biliary tract cancer. The Company recently anno